v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Grant Revenue $ 227,629 $ 0 $ 227,629 $ 0
Operating expenses:        
Research and development 1,304,345 116,383 2,054,158 191,915
General and administrative 1,326,676 849,182 2,860,602 2,492,345
Total operating expenses 2,631,021 965,565 4,914,760 2,684,260
Loss from operations (2,631,021) (965,565) (4,914,760) (2,684,260)
Interest income and other, net 29,592 7,740 88,703 16,902
Net loss $ (2,373,800) $ (957,825) $ (4,598,428) $ (2,667,358)
Net loss per share attributable to common stockholders - basic $ (4.46) $ (81.21) $ (8.64) $ (253.72)
Net loss per share attributable to common stockholders - diluted (4.46) (81.21) (8.64) (253.72)
Total net loss per share - basic (4.46) (81.21) (8.64) (253.72)
Total net loss per share - diluted $ (4.46) $ (81.21) $ (8.64) $ (253.72)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic 531,968 11,794 531,968 10,513
Weighted-average number of common shares used in net loss per share attributable to common stockholders - diluted 531,968 11,794 531,968 10,513